From owner-sci-resources@net.bio.net Mon Apr 04 23:00:00 1994 Path: biosci!biosci!not-for-mail From: Dave Kristofferson Newsgroups: bionet.sci-resources Subject: NSF - Summary of new documents on STIS - 3 April 1994 Date: 4 Apr 1994 17:24:22 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 129 Approved: biosci-moderator@net.bio.net Distribution: bionet Message-ID: <2nqb3m$m8g@net.bio.net> NNTP-Posting-Host: net.bio.net This message contains a summary of the documents added to the NSF STIS system in the previous week. Reference material concerning STIS follows the summary. ------------------------------------------------------------------------ ** NEW DOCUMENTS ON STIS ** Document Type: Bulletin Title: BUL 9404 -- NSF April Bulletin Vol. 21, No. 8 File size (bytes): 39771 STIS Filename: bul9404 Document Type: Form Title: FM CERT - GPG Certification Page File size (bytes): 747 STIS Filename: fmcert Also available: fmcert.ps Document Type: Letter Title: IAI/IC NEWSLETTER File size (bytes): 49381 STIS Filename: ltriaiic Title: NSF 94-54 ENGINEERING NEWSLETTER File size (bytes): 5143 STIS Filename: nsf9454 Document Type: Press Release Title: NSF-FUNDED COMPUTER SIMULATION REVEALS ALZHEIMER'S - GLAUCOMA ENZYME File size (bytes): 3739 STIS Filename: pr9418 Title: TOOTH OF LARGE FOSSIL MAMMAL DISCOVERED IN MADAGASCAR BY NSF-FUNDED SCIENTIST File size (bytes): 3692 STIS Filename: pr9419 Document Type: Program Guideline Title: NSF 94-34 - Rural Systemic Initiatives in Science, Mathematics and Technology Education File size (bytes): 38029 STIS Filename: nsf9434 Title: NSF 94-46 File size (bytes): 25378 STIS Filename: nsf9446 Title: NSF 94-50 -- National Earthquake Hazards Reduction Program An Investigation Into the Cause and Effects of the Northridge Earthquake of January 17, 1994 File size (bytes): 33920 STIS Filename: nsf9450 ------------------------------------------------------------------------ ** UPDATES TO EXISTING STIS DOCUMENTS ** Document Type: Form Title: FM 1030 - GPG Summary Proposal Budget Form File size (bytes): 756 STIS Filename: fm1030 Also available: fm1030.ps Title: FM 1359 - GPG Table of Contents Form File size (bytes): 750 STIS Filename: fm1359 Also available: fm1359.ps Title: FM 1363 - GPG Facilities, Equipment & Other Resources Form File size (bytes): 772 STIS Filename: fm1363 Also available: fm1363.ps Title: NSF 94-3 - Grant Proposal Guide Forms Kit File size (bytes): 1278 STIS Filename: nsf943 Also available: nsf943.zip Document Type: Letter Title: Current List of REU Sites File size (bytes): 54806 STIS Filename: reulist ------------------------------------------------------------------------ ** FOR YOUR REFERENCE ** ------------------------------------------------------------------------ HOW TO OBTAIN DOCUMENTS The above files can be retrieved in electronic form using the STIS system. If you don't know how to use STIS, send an E-mail message to stisinfo@nsf.gov (Internet). You will receive a copy of the STIS flyer via E-mail. If you are already using STIS, you can use the information above to retrieve these files: Documents via E-mail: Send a message to stisserve@nsf.gov (Internet). Use the "STIS Filename" shown above in the "get" command. For example, to retrieve reulist, the text of your message should be as follows: get reulist Anonymous FTP: FTP to stis.nsf.gov. Use the "STIS Filename" shown above to retrieve a file. For example, to retrieve reulist, you would enter: ftp> get reulist WAIS or Gopher: Do a word search on the filename as shown in the summary. If you want a *printed* copy of a document: Send your name and postal mailing address, and the document title and number to "pubs@nsf.gov" (Internet). If you have problems with the above procedures: Send a message to "stis@nsf.gov" (Internet). From owner-sci-resources@net.bio.net Tue Apr 05 23:00:00 1994 Path: biosci!biosci!not-for-mail From: Dave Kristofferson Newsgroups: bionet.sci-resources Subject: NIH Guide, vol. 23, no. 13, 1 April 1994 Date: 5 Apr 1994 17:01:09 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 1564 Approved: biosci-moderator@net.bio.net Distribution: bionet Message-ID: <2nsu45$422@net.bio.net> NNTP-Posting-Host: net.bio.net $$XID NIHGUIDE 19940401 V23N13 P1O2 ************************************ X-comment: RFAS described: CA-94-011, CA-94-012, AR-94-005, HL-94-012, HL-94- 013 NIH GUIDE - Vol. 23, No. 13 - April 1, 1994 $$INDEX BEGIN ******************************************************* NOTICES OF AVAILABILITY (RFPs AND RFAs) $$INDEX R1 ********************************************************** EVALUATION OF CHEMOPREVENTIVE AGENTS BY IN VIVO SCREENING ASSAYS (RFP NCI-CN-45000-46) National Cancer Institute INDEX: CANCER $$INDEX R2 ********************************************************** DETERMINATION OF SERUM ANTIBODIES TO PERIODONTAL PATHOGENS IN THE U.S. POPULATION (RFP NIH-NIDR-2-94-7R) National Institute of Dental Research INDEX: DENTAL RESEARCH $$INDEX R3 06/16/94 ************************************************* BREAST CANCER EDUCATION INITIATIVES (RFA CA-94-011) National Cancer Institute INDEX: CANCER $$INDEX R4 06/16/94 ************************************************* HOSPICE AND PALLIATIVE CARE EDUCATION PROGRAMS (RFA CA-94-012) National Cancer Institute INDEX: CANCER $$INDEX R5 07/26/94 ************************************************* BASIC OSTEOPOROSIS NEW EXPERIMENTAL STRATEGIES (RFA AR-94-005) National Institute of Arthritis and Musculoskeletal and Skin Diseases National Institute of Diabetes and Digestive and Kidney Diseases National Institute on Aging INDEX: ARTHRITIS, MUSCULOSKELETAL, SKIN DISEASES; DIABETES, DIGESTIVE, KIDNEY DISEASES; AGING $$INDEX R6 09/15/94 ************************************************* SPECIALIZED CENTERS OF RESEARCH: TRANSFUSION BIOLOGY AND MEDICINE (RFA HL-94-012) National Heart, Lung, and Blood Institute INDEX: HEART, LUNG, BLOOD $$INDEX R7 09/15/94 ************************************************* SPECIALIZED CENTERS OF RESEARCH: HEMOSTATIC AND THROMBOTIC DISEASES (RFA HL-94-013) National Heart, Lung, and Blood Institute INDEX: HEART, LUNG, BLOOD ONGOING PROGRAM ANNOUNCEMENTS $$INDEX P1 ********************************************************** AGING AND BONE QUALITY (PA-94-052) National Institute on Aging National Institute of Arthritis and Musculoskeletal and Skin Diseases INDEX: AGING; ARTHRITIS, MUSCULOSKELETAL, SKIN DISEASES ADDENDUM $$INDEX A1 ********************************************************** GRANT WRITING WORKSHOP FOR NUTRITION FOR PROGRAM ANNOUNCEMENT PA-94- 033 National Cancer Institute INDEX: CANCER This publication is available electronically to institutions via BITNET or INTERNET and is also on the NIH GOPHER. Alternative access is through the NIH Grant Line using a personal computer (data line 301/402-2221). Contact Dr. John James at 301/594-7270 for details. THE PUBLIC HEALTH SERVICE (PHS) STRONGLY ENCOURAGES ALL GRANT RECIPIENTS TO PROVIDE A SMOKE-FREE WORKPLACE AND PROMOTE THE NON-USE OF ALL TOBACCO PRODUCTS. THIS IS CONSISTENT WITH THE PHS MISSION TO PROTECT AND ADVANCE THE PHYSICAL AND MENTAL HEALTH OF THE AMERICAN PEOPLE. $$INDEX END ********************************************************* NOTICES OF AVAILABILITY (RFPs AND RFAs) $$R1 BEGIN NCI-CN-45000-46 ****************************************** EVALUATION OF CHEMOPREVENTIVE AGENTS BY IN VIVO SCREENING ASSAYS NIH GUIDE, Volume 23, Number 13, April 1, 1994 RFP AVAILABLE: NCI-CN-45000-46 P.T. National Cancer Institute The National Cancer Institute (NCI), Division of Cancer Prevention and Control, Chemoprevention Branch, wishes to award Master Agreement (MA) contracts for the evaluation of chemopreventive agents by in vivo screening assays. The required services will be defined by Master Agreement Orders (MAO) issued during the four year period of performance. This solicitation is the annual announcement to expand the current pool of MA Holders qualified to perform this type of work. All interested offerors must submit proposals to be eligible to compete for future MAO RFPs. Pursuant to the MAO the Contractor will conduct in vivo screening studies in small rodents using gavage and other routes of administration to administer the designated chemopreventive agents in animal models using any carcinogenic mechanism (that is consistent with the Evaluation Criteria), such as the administration of carcinogens, promoters, hormones, irradiation, cells or other carcinogenic agents. Agents to be tested are potentially hazardous. The animal model systems also involve the use of carcinogens. Laboratory practices that keep any element of risk to personnel at an absolute minimum will be employed. Where indicated, tissue and compound handling must be performed in (at least) Class I laminar flow agents. It is required that the animal facilities be maintained in accordance with the NIH Guide for the Care and Use of Laboratory Animals, the Animal Welfare Act as administered by the USDA, and the U.S. Government Principals for Utilization and Care of Vertebrate Animals Used for Testing Research and Training. This research will be performed under cost reimbursement and/or fixed price MAO's. The contractor must have all the equipment necessary to accomplish the studies including, but not limited to, animal racks and caging, hazardous chemical storage cabinets and refrigerators, pathology equipment such as microscopes and microtomes and miscellaneous laboratory equipment. The laboratory must have or have access to appropriate terminal and computer facilities and equipment for data collection and storage. It is estimated that four to five Task Orders per year will be issued pursuant to the Master Agreement contracts. The Master Agreement Announcement will be available on approximately March 25, 1994. Proposal due date will be approximately May 24, 1994. INQUIRIES Copies of the MAA/RFP NCI-CN-45000-46 may be obtained by sending a written request to: Mr. Schuyler T. Eldridge Research Contracts Branch National Cancer Institute Executive Plaza South, Suite 635, Bethesda, MD 20892 Telephone: (301) 496-8603 Collect calls will not be accepted. $$R1 END ************************************************************ $$R2 BEGIN NIH-NIDR-2-94-7R ***************************************** DETERMINATION OF SERUM ANTIBODIES TO PERIODONTAL PATHOGENS IN THE U.S. POPULATION NIH GUIDE, Volume 23, Number 13, April 1, 1994 RFP AVAILABLE: NIH-NIDR-2-94-7R P.T. National Institute of Dental Research The National Institute of Dental Research (NIDR) has a requirement for a state-licensed microbiology laboratory capable of processing thousands of serum samples for antibodies to periodontal pathogens, including the capability of receiving and transporting the samples. The objective of this study is to determine the occurrence of elevated serum antibodies to periodontal pathogens in a sample of persons examined in the Third National Health and Nutrition Examination Survey (NHANES III). Serum from the NHANES III subjects has already been collected, frozen, and stored for further analysis. The serum must be assayed by ELISA procedures. Request for Proposals (RFP) NIH-NIDR-2-94-7R will be available on or about April 12, 1994, with proposals due May 12, 1994. It is anticipated that one award will be made as a result of this solicitation. INQUIRIES The RFP package is available by written request to: Marilyn R. Zuckerman Contract Management Office National Institute of Dental Research Westwood Building, Room 533 Bethesda, MD 20892 $$R2 END ************************************************************ $$R3 BEGIN CA-94-011 FULL-TEXT ************************************** BREAST CANCER EDUCATION INITIATIVES NIH GUIDE, Volume 23, Number 13, April 1, 1994 RFA AVAILABLE: CA-94-011 P.T. National Cancer Institute Letter of Intent Receipt Date: May 2, 1994 Application Receipt Date: June 16, 1994 THIS IS A NOTICE OF AVAILABILITY OF A REQUEST FOR APPLICATIONS (RFA); IT IS ONLY AN ABSTRACT OF THE RFA. POTENTIAL APPLICANTS MUST REQUEST THE COMPLETE RFA, WHICH CONTAINS ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION, FROM THE CONTACT LISTED IN "INQUIRIES," BELOW. FAILURE TO FOLLOW THE INSTRUCTIONS IN THE COMPLETE RFA MAY RESULT IN AN INCOMPLETE APPLICATION, WHICH WILL BE RETURNED TO THE APPLICANT WITHOUT REVIEW. PURPOSE The National Cancer Institute (NCI) invites grant applications to create new educational programs aimed at reducing the mortality and morbidity of breast cancer. These cancer education programs are intended to disseminate what is professionally known about the prevention, early detection, and treatment of breast cancer to primary care physicians, other health professionals, and the lay community with special attention to minority or underserved populations. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Breast Cancer Education Initiatives, is related to the priority area of cancer. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic for-profit and non-profit organizations, public and private, such as universities, colleges, Cancer Centers, hospitals, Laboratories, units of State and local governments, and eligible agencies of the Federal government. Foreign organizations are not eligible to apply. Applications from minority individuals and women are encouraged. MECHANISM OF SUPPORT Support for this program will be through the NCI Cancer Education (R25) Award. This is a flexible, curriculum-driven program aimed at developing and sustaining innovative and, possibly, unique educational approaches that ultimately will have an impact on reducing cancer incidence, mortality, and morbidity, as well as on improving the quality-of-life of cancer patients. The current guidelines for the Cancer Education Program (R25) may be obtained from the program director listed under INQUIRIES. Applicants will be responsible for the planning, direction, and execution of the proposed project. The total project period for applications submitted in response to this RFA may not exceed three years. It is anticipated that the average amount of direct costs awarded per grant will range from $50,000 to $130,000 depending upon the proposed program. Indirect costs will be allowed at the rate of eight percent of total direct costs (exclusive of equipment). The earliest feasible start date for the initial award will be September 1994. This RFA is a one-time solicitation. Future competitive continuation applications will compete with all other applications in the Cancer Education Grant Program (R25). However, if the NCI determines that there is a sufficient program need, a new request for competitive continuation and/or new applications will be announced. FUNDS AVAILABLE For FY 1994, $1,600,000 in total costs will be available for, it is estimated, some 15 to 20 awards. This funding level is dependent on the receipt of a sufficient number of applications of high scientific merit. A greater or lesser amount of dollars and number of awards may be negotiated based on the quality of the applications and the availability of funds. RESEARCH OBJECTIVES The purpose of this RFA is to stimulate breast cancer educational programs among health professionals and the lay public. The NCI proposes that Cancer Centers and other organizations with appropriate breast cancer expertise collaborate with educational specialists and other professional and lay groups, particularly those with access to underserved populations, to design and implement programs dealing with one or more of the following target populations for this initiative: primary care physicians, health professional faculty, health professional students, women's groups, minority or underserved groups, employer-based groups, breast cancer patients and their families. The NCI also strongly encourages submission of applications from minority health professional schools and from other organizations that have traditionally served minority communities and geographically isolated populations. SPECIAL REQUIREMENTS If several institutions are jointly involved or if several departments within an institution are cooperating in this RFA, a special, central, interdisciplinary Cancer Education Committee consisting of members from the collaborating organizations should be in place. The functions of the Committee would be to provide effective monitoring and coordination of the program. LETTER OF INTENT Prospective applicants are asked to submit, by May 2, 1994, a letter of intent that includes a descriptive title of the proposed educational proposal, the name, address, and telephone number of the Principal Investigator/Educator, the identities of other key personnel and participating institutions, and the number and title of the RFA in response to which the application may be submitted. Although a letter of intent is not required, is not binding, and does not enter into the review of subsequent applications, the information that it contains allows NCI staff to estimate the potential review workload and to avoid conflict of interest in the review. The letter of intent is to be sent to Dr. Robert C. Adams at the address listed under INQUIRIES. APPLICATION PROCEDURES The research grant application form PHS 398 (rev. 9/91) is to be used in applying for these grants. These forms are available at most institutional offices of sponsored research; from the Office of Grants Information, Division of Research Grants, National Institutes of Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone (301) 594-7248; and from the NCI Program Director listed under INQUIRIES. Applications must be received by June 16, 1994. REVIEW CONSIDERATIONS Applications will be reviewed by an appropriate review group convened by the Division of Extramural Activities, NCI. Consult the RFA for additional details. AWARD CRITERIA The anticipated date of award is September, 1994. Awards will be made according to priority score, availability of funds, and programmatic priorities. INQUIRIES Written and telephone requests for the RFA and the opportunity to clarify any issues or questions from potential applicants are welcome. Direct requests for the RFA, inquiries regarding programmatic issues, and address the letter of intent to: Dr. Robert C. Adams Division of Cancer Biology, Diagnosis, and Centers National Cancer Institute Executive Plaza North, Room 520 Bethesda, MD 20892 Telephone: (301) 496-8580 FAX: (301) 402-4472 Direct inquiries regarding grants management issues to: Mr. Robert Hawkins Grants Administration Branch National Cancer Institute Executive Plaza South, Room 242 Bethesda, MD 20892 Telephone: (301) 496-7800, ext. 213 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance Number 93.398, Cancer Research Manpower. Awards are made under the authorization of the Public Health Service Act, Title IV, Part A, Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285 and administered under HHS regulations and PHS grant policies. $$R3 END ************************************************************ $$R4 BEGIN CA-94-012 FULL-TEXT ************************************** HOSPICE AND PALLIATIVE CARE EDUCATION PROGRAMS NIH GUIDE, Volume 23, Number 13, April 1, 1994 RFA AVAILABLE: CA-94-012 P.T. National Cancer Institute Letter of Intent Receipt Date: May 2, 1994 Application Receipt Date: June 16, 1994 THIS IS A NOTICE OF AVAILABILITY OF A REQUEST FOR APPLICATIONS (RFA); IT IS ONLY AN ABSTRACT OF THE RFA. POTENTIAL APPLICANTS MUST REQUEST THE COMPLETE RFA, WHICH CONTAINS ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION, FROM THE CONTACT LISTED IN "INQUIRIES," BELOW. FAILURE TO FOLLOW THE INSTRUCTIONS IN THE COMPLETE RFA MAY RESULT IN AN INCOMPLETE APPLICATION, WHICH WILL BE RETURNED TO THE APPLICANT WITHOUT REVIEW. PURPOSE The National Cancer Institute (NCI) invites grant applications to create new educational programs to address health professional training in palliative patient care. The intent of this RFA is to emphasize NCI's concern for this neglected area with the expectation that any funded programs will act as catalysts to encourage further interest and development in the medical community. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Hospice and Palliative Care Education Programs, is related to the priority area of Educational and Community-based Programs. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic for-profit and non-profit organizations, public and private, such as universities, colleges, cancer centers, hospitals, hospices, units of State and local governments, and eligible agencies of the Federal government. Foreign organizations are not eligible to apply. Applications from minority individuals and women are encouraged. MECHANISM OF SUPPORT Support for this effort will be through the NCI Cancer Education (R25) Award. This is a flexible, curriculum-driven program aimed at developing and sustaining innovative and, possibly, unique educational approaches that ultimately will have an impact on reducing cancer incidence, mortality, and morbidity, as well as on improving the quality-of-life of cancer patients and their families. The current guidelines for the Cancer Education Program (R25) may be obtained from the program director listed under INQUIRIES. Applicants will be responsible for the planning, direction, and execution of the proposed project. The total project period for applications submitted in response to this RFA may not exceed three years. The earliest feasible start date for the initial award will be September 1994. It is anticipated that the average amount of direct costs awarded per grant will range from $50,000 to $100,000 depending upon the proposed program. Indirect costs will be allowed at the rate of eight percent of total direct costs (exclusive of equipment). This RFA is a one-time solicitation. Future competitive continuation applications will compete with all other applications in the Cancer Education Grant Program (R25). However, if the NCI determines that there is a sufficient program need, a new request for competitive continuation and/or new applications will be announced. FUNDS AVAILABLE For FY 1994, $500,000 in total costs will be available for, it is estimated, some five to seven awards. This funding level is dependent on the receipt of a sufficient number of applications of high scientific merit. A greater or lesser amount of dollars and number of awards may be negotiated based on the quality of the applications and the availability of funds. RESEARCH OBJECTIVES This RFA proposes to stimulate medical schools, schools of nursing, cancer centers, oncology divisions, and other health professional entities to design methodologies for the education and training of health care professionals in hospice and palliative care. Hospices, either individually or in regional settings in collaborative arrangements with other medical centers are particularly encouraged to submit applications in response to this RFA. The NCI hopes to stimulate multi-disciplinary, team approaches to palliative care by encouraging a variety of educational programs aimed at medical students, physicians, other health professionals, and hospice personnel. The ultimate goal is to benefit cancer patients and their families. SPECIAL REQUIREMENTS If several institutions are jointly involved or if several departments within an institution are cooperating in this RFA, a special, central, interdisciplinary Cancer Education Committee consisting of members from the collaborating organizations or units should be in place. The functions of the Committee would be to provide effective monitoring and coordination of the program. LETTER OF INTENT Prospective applicants are asked to submit, by May 2, 1994, a letter of intent that includes a descriptive title of the proposed educational proposal, the name, address, and telephone number of the Principal Investigator/Educator, the identities of other key personnel and participating institutions, and the number and title of the RFA in response to which the application may be submitted. Although a letter of intent is not required, is not binding, and does not enter into the review of subsequent applications, the information that it contains allows NCI staff to estimate the potential review workload and to avoid conflict of interest in the review. The letter of intent is to be sent to Dr. Robert C. Adams at the address listed under INQUIRIES. APPLICATION PROCEDURES The research grant application form PHS 398 (rev. 9/91) is to be used in applying for these grants. These forms are available at most institutional offices of sponsored research; from the Office of Grants Information, Division of Research Grants, National Institutes of Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone 301/594-7248; and from the NCI Program Director listed under INQUIRIES. Applications must be received by June 16, 1994. REVIEW CONSIDERATIONS Applications will be reviewed for scientific and technical merit by an appropriate peer review group convened by the Division of Extramural Activities, NCI. Consult the RFA for additional details. AWARD CRITERIA The anticipated date of award is September, 1994. Awards will be made according to priority score, availability of funds, and programmatic priorities. INQUIRIES Written and telephone requests for the RFA and the opportunity to clarify any issues or questions from potential applicants are welcome. Direct requests for the RFA, inquiries regarding programmatic issues, and address the letter of intent to: Dr. Robert C. Adams Division of Cancer Biology, Diagnosis, and Centers National Cancer Institute Executive Plaza North, Room 520 Bethesda, MD 20892 Telephone: (301) 496-8580 FAX: (301) 402-4472 Direct inquiries regarding grants management matters to: Mr. Robert Hawkins Grants Administration Branch National Cancer Institute Executive Plaza South, Room 242 Bethesda, MD 20892 Telephone: (301) 496-7800, ext. 213 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance Number 93.398, Cancer Research Manpower. Awards are made under the authorization of the Public Health Service Act, Title IV, Part A, Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285 and administered under HHS regulations and PHS grant policies. $$R4 END ************************************************************ $$R5 BEGIN AR-94-005 FULL-TEXT ************************************** BASIC OSTEOPOROSIS NEW EXPERIMENTAL STRATEGIES NIH GUIDE, Volume 23, Number 13, April 1, 1994 RFA AVAILABLE: AR-94-005 P.T. National Institute of Arthritis and Musculoskeletal and Skin Diseases National Institute of Diabetes and Digestive and Kidney Diseases National Institute on Aging Letter of Intent Receipt Date: June 28, 1994 Application Receipt Date: July 26, 1994 THIS IS A NOTICE OF AVAILABILITY OF A REQUEST FOR APPLICATIONS (RFA); IT IS ONLY AN ABSTRACT OF THE RFA. POTENTIAL APPLICANTS MUST REQUEST THE COMPLETE RFA, WHICH CONTAINS ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION, FROM THE CONTACT LISTED IN "INQUIRIES," BELOW. FAILURE TO FOLLOW THE INSTRUCTIONS IN THE COMPLETE RFA MAY RESULT IN AN INCOMPLETE APPLICATION, WHICH WILL BE RETURNED TO THE APPLICANT WITHOUT REVIEW. PURPOSE The Bone Biology and Bone Diseases Branch of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the Bone and Mineral Research Program of the Endocrinology Research Section of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and the Geriatrics and Biology of Aging Programs of the National Institute on Aging (NIA) invite investigator-initiated research project grant applications to encourage and facilitate research projects designed to develop promising basic cellular, molecular, physiological, and genetic approaches to osteoporosis. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Basic Osteoporosis New Experimental Strategies, is related to the priority areas of diabetes and chronic disabling conditions and older adults and preventive services. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic and foreign for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal government. Foreign institutions are not eligible for First Independent Research Support and Transition (FIRST) (R29) awards. Applications from women and minority individuals are encouraged. MECHANISM OF SUPPORT Support for this program will be through investigator-initiated research grant applications (R01) and FIRST (R29) awards. This RFA is a one-time solicitation for fiscal year 1995. The total project period for applications submitted in response to the present RFA may not exceed four years. FIRST (R29) awards must be for five years. The anticipated award date is April 1, 1995. FUNDS AVAILABLE Approximately $2,000,000 in total costs per year for four years will be committed by the NIAMS to fund applications submitted in response to this RFA. An additional $500,000 will be committed by the NIDDK, and an additional $600,000 by the NIA. The direct cost of each R01 project is limited to $160,000 for the first year and each R29 is --- . Thus it is anticipated that a total of 12 to 14 projects will be funded in FY 95. Applicants from institutions that have a General Clinical Research Center (GCRC) funded by the NIH National Center for Research Resources may wish to identify the GCRC as a resource for conducting the proposed research. If so, a letter of agreement from either the GCRC program director or Principal Investigator should be included with the application. RESEARCH OBJECTIVES Effective approaches to the treatment of established osteoporosis are urgently needed. Such new therapeutic approaches are most likely to arise from improved understanding of the basic biology of bone growth and maintenance. In order to capitalize on current scientific opportunities, it is necessary to integrate biological insights and methodologies from a broad range of specialties. The overall goal of the BONES initiative is to encourage and support new basic research in the areas of bone structure, formation, remodeling, and repair. This initiative is designed to (1) encourage established bone biology investigators to address osteoporosis-related problems with novel approaches and the most powerful methodologies available; (2) increase the pool of investigators working in osteoporosis-related basic science areas by drawing researchers from genetics, cell and molecular biology, and structural chemistry into bone research; and (3) foster the development of interactions between laboratories originating in different disciplines. STUDY POPULATIONS INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS Awards for research involving human subjects must follow the "NIH Guidelines On the Inclusion of Women and Minorities as Subjects in Clinical Research." See the RFA for details. LETTER OF INTENT Prospective applicants are asked to submit, by June 28, 1994, a letter of intent that includes a descriptive title of the proposed research, the name, address, and telephone number of the Principal Investigator, the identities of other key personnel and participating institutions, and the number and title of the RFA in response to which the application may be submitted. The letter of intent is to be sent to Dr. William Sharrock at the address listed under INQUIRIES. APPLICATION PROCEDURES The research grant application form PHS 398 (rev. 9/91) is to be used in applying for this RFA. These forms are available at most institutional offices of sponsored research; from the Office of Grants Information, Division of Research Grants, National Institutes of Health, 5333 Westbard Avenue, Room 449, Bethesda, MD 20892, telephone 301/ 594-7248; and from the program staff listed under INQUIRIES. The RFA label available in the PHS 398 (rev. 9/91) application form must be affixed to the bottom of the face page of the application. In addition, the RFA title and number must be typed on line 2a of the face page of the application form and the YES box must be marked. Applications for the FIRST Award (R29) must include at least three sealed letters of reference attached to the face page of the original application. FIRST Award (R29) applications submitted without the required number of reference letters will be considered incomplete and will be returned without review. Submit a signed, typewritten original of the application, including the Checklist, and three signed photocopies, in one package to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** At the time of submission, two additional copies of the application must also be sent to: Dr. Tommy Broadwater Review Branch National Institute of Arthritis and Musculoskeletal and Skin Diseases Westwood Building, Room 406 Bethesda, MD 20892 Telephone: (301) 594-9979 FAX: (301) 594-9673 Applications must be received by July 26, 1994. REVIEW CONSIDERATIONS Applications may be triaged by an NIAMS peer review group on the basis of relative competitiveness. The NIH will withdraw from further competition those applications judged to be non-competitive for award and notify the applicant Principal Investigator and institutional official. Those applications judged to be competitive will undergo further scientific merit review. Those applications that are complete and responsive will be evaluated in accordance with the criteria stated below for scientific/technical merit by an appropriate peer review group convened by the NIAMS. The second level of review will be provided by the NIAMS, NIDDK, and NIA advisory councils. Review criteria for RFAs are generally the same as those for unsolicited research grant applications. AWARD CRITERIA The anticipated date of award is April 1, 1995. In addition to the technical merit of the application as reflected in the priority score, the NIAMS, NIDDK, and NIA will consider how well the applicant institution meets the goals and objectives of the program as described in the RFA, availability of resources and/or study populations. INQUIRIES Written and telephone requests for the RFA and the opportunity to clarify any issues or questions from potential applicants are welcome. Direct requests for the RFA and inquiries regarding programmatic issues to: William Sharrock, Ph.D. Bone Biology and Bone Diseases Branch National Institute of Arthritis and Musculoskeletal and Skin Diseases Westwood Building, Room 403 Bethesda, MD 20892 Telephone: (301) 594-9975 FAX: (301) 594-9673 Ronald Margolis, Ph.D. Endocrinology Research Section National Institute of Diabetes and Digestive and Kidney Diseases Westwood Building, Room 621 Bethesda, MD 20892 Telephone: (301) 594-7549 FAX: (301) 594-9011 Sherry Sherman, Ph.D. Geriatrics Program National Institute on Aging Gateway Building, Suite 2C218 7201 Wisconsin Avenue Bethesda, MD 20892 Telephone: (301) 496-9322 FAX: (301) 402-2945 Direct inquiries regarding fiscal matters to: G. Carol Fitzpatrick Grants Management Office National Institute of Arthritis and Musculoskeletal and Skin Diseases Westwood Building, Room 722A Bethesda, MD 20892 Telephone: (301) 594-9974 FAX: (301) 594-9950 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance Nos. 93.846, 93.847, and 93.866. Awards will be made under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 410, 78th Congress, as amended, 42 USC 241 and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. $$R5 END ************************************************************ $$R6 BEGIN HL-94-012 FULL-TEXT ************************************** SPECIALIZED CENTERS OF RESEARCH: TRANSFUSION BIOLOGY AND MEDICINE NIH GUIDE, Volume 23, Number 13, April 1, 1994 RFA AVAILABLE: HL-94-012 P.T. National Heart, Lung, and Blood Institute Letter of Intent Receipt Date: May 31, 1994 Application Receipt Date: September 15, 1994 THIS IS A NOTICE OF AVAILABILITY OF A REQUEST FOR APPLICATIONS (RFA); IT IS ONLY AN ABSTRACT OF THE RFA. POTENTIAL APPLICANTS MUST REQUEST THE COMPLETE RFA, WHICH CONTAINS ESSENTIAL INFORMATION FOR THE PREPARATION OF THE APPLICATION, FROM THE CONTACT LISTED IN THE "INQUIRIES," BELOW. FAILURE TO FOLLOW THE INSTRUCTIONS IN THE COMPLETE RFA MAY RESULT IN AN INCOMPLETE APPLICATION, WHICH WILL BE RETURNED TO THE APPLICANT WITHOUT REVIEW. PURPOSE The objectives of the Specialized Centers of Research (SCOR) program in Transfusion Biology and Medicine are to improve the safety and efficacy of blood and blood components, define the indications for their use, evaluate and possibly modify immunological responsiveness following their administration, and develop and evaluate alternative treatment strategies that substitute for certain of their functions or stimulate their endogenous production so as to reduce transfusion needs. This initiative also encourages the use of new and innovative technologies to pursue fundamental research studies in transfusion biology and clinical investigations in transfusion medicine. The goals of this program are to understand better the basic biology of transfusion; make optimal use of blood, blood components, and plasma protein derivatives in specific replacement therapy; improve transfusion practice; and perform basic and applied research on blood substitutes. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Specialized Centers of Research in Transfusion Biology and Medicine, is related to the priority area of maternal and infant health. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by for-profit and non-profit domestic institutions, public and private, such as universities, colleges, hospitals, and laboratories. Awards will not be made to foreign institutions. However, under exceptional circumstances, a foreign component critical to a project may be included as a part of that project. Women and minority investigators are encouraged to apply. MECHANISM OF SUPPORT This RFA will use the National Heart, Lung, and Blood Institute (NHLBI) SCOR (P50) grant to support this research program. Responsibility for the planning, direction, and execution of the proposed project will be solely that of the applicant. All current policies and requirements that govern the research grant programs of the NIH will apply to grants awarded under this RFA. Basic and Clinical Research It is essential that all applications include both basic and clinical research. Interactions between basic and clinical scientists are expected to strengthen the research, enhance transfer of fundamental research findings to the clinical setting, and identify new research directions. Applications that include only basic or only clinical research will not be responsive to this RFA. In addition, clinical research projects focused on large epidemiologic studies or large clinical trials will be considered unresponsive to this RFA. FUNDS AVAILABLE Up to $1,125,000 in direct costs, not including indirect costs for collaborating institutions, in the first year with a maximum increase of no more than four percent in each additional year may be requested in each application. Award of grants pursuant to this RFA is contingent upon receipt of funds for this purpose. It is anticipated that at least two SCOR grants will be funded. NHLBI's FY 1996 plans for this initiative include a maximum of $4.4 million. The specific amount to be funded will, however, depend on the merit and scope of the applications received and on the availability of funds. RESEARCH OBJECTIVES Background During the past decade, significant scientific advances have been made in transfusion medicine that have improved the safety and quality of blood, blood components and plasma derivatives and have changed transfusion practices. Advances have been made in detecting evidence of viral pathogens such as HIV-1, HIV-2, HTLV-I/HTLV-II and hepatitis C in donated blood, thus preventing such agents from entering the blood supply. Moreover, procedures have been developed to inactivate viruses in plasma derivatives and soon in plasma itself. Improved apheresis technologies have been developed that permit more efficient collection and manipulation of blood components and bone marrow. Investigators have described properties of newly developed plasma derivatives. Techniques have been developed that may lead to the use of stem cells from umbilical cord blood for bone marrow transplantation. As a result, the importance of blood transfusion has been greatly expanded through the use of components and derivatives in increasingly specialized and effective forms of therapy. The use of blood and blood components continues to increase. Improved patient care, including aggressive cancer chemotherapy programs, bone marrow transplantation and sophisticated cardiac surgery procedures have contributed heavily to this growth which is expected to continue into the future. Consequently, the implementation of research programs to determine the optimal use of this valuable resource is important and timely. Proposed Research The principal research aim of this RFA is to encourage basic and clinical research towards the optimal use and improvement of transfusion therapy. Recent progress in our understanding in such areas as immune regulation and hematopoiesis make this an opportune time to encourage research in the following areas of emphasis: (1) immunomodulatory aspects of transfusion; (2) development of novel cell therapies and cytokine therapies; (3) structure/function relationships of human blood cell surface antigens; (4) blood substitutes; and (5) indications for red cell or platelet transfusion. The topics may address one or more than one area of emphasis. For example, it would be appropriate for a SCOR applicant to propose projects that address research issues pertaining to one area of interest such as structure/function relationships of human blood cell surface antigens or a combination such as structure/function relationships of human blood cell surface antigens and immunomodulatory aspects of transfusion. Applicants should also note that a SCOR program must meet the following criteria: (1) address areas of significant national need and clinical importance; (2) attract talented investigators who foster the development of a multidisciplinary and collaborative synergistic approach; (3) include both basic and clinical components; and, most importantly; (4) have the potential to accelerate the transfer of basic research to clinical application. STUDY POPULATIONS INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS Awards for research involving human subjects must follow the "NIH Guidelines On the Inclusion of Women and Minorities as Subjects in Clinical Research." See the RFA for details. LETTER OF INTENT Prospective applicants are asked to submit, by May 31, 1994, a letter of intent that includes a descriptive title of the proposed research; the name, address, and telephone number of the principal investigator; the identities of other key personnel and participating institutions; and the number and title of the RFA in response to which the application may be submitted. Although a letter of intent is not required, is not binding, and does not enter into the review of subsequent applications, the information that it contains is helpful in planning for the review of applications. It allows NHLBI staff to estimate the potential review workload and to avoid conflict of interest in the review. The letter of intent is to be sent to: Chief, Review Branch Division of Extramural Affairs National Heart, Lung and Blood Institute Westwood Building, Room 557A Bethesda, MD 20892 REVIEW CONSIDERATIONS Applications will be judged on the basis of the scientific and technical merit of the proposed research; the qualifications and research experience of the investigators; the collaborative interaction among basic and clinical research components; the adequacy of the environment; and the appropriateness of the budget. APPLICATION PROCEDURES The research grant application form PHS 398 (rev. 9/91) is to be used in applying for these grants. These forms are available at most institutional offices of sponsored research and may be obtained from the Office of Grants Information, Division of Research Grants, National Institutes of Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone 301/594-7248. Applications must be received by September 15, 1994 INQUIRIES Written and telephone requests for the RFA and the opportunity to clarify issues or questions from potential applicants are welcome. Direct inquiries regarding scientific issues and requests for the RFA to: George J. Nemo, Ph.D. Division of Blood Diseases and Resources National Heart, Lung, and Blood Institute Federal Building, Room 504 Bethesda, MD 20892 Telephone: (301) 496-1537 FAX: (301) 402-4843 Direct inquiries regarding fiscal and administrative matters to: Ms. Jane Davis Division of Extramural Affairs National Heart, Lung and Blood Institute Westwood Building, Room 4A15C Bethesda, MD 20892 Telephone: (301) 594-7436 FAX: (301) 594-7492 AUTHORITY AND REGULATIONS The programs of the Division of Blood Diseases and Resources, NHLBI, are described in the Catalog of Federal Domestic Assistance No. 93.839. Awards will be made under the authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirement of Executive Order 12372 or Health Systems Agency review. All current policies and requirements that govern the research grant programs of the NIH will apply to grants awarded under this RFA. $$R6 END ************************************************************ $$R7 BEGIN HL-94-013 FULL-TEXT ************************************** SPECIALIZED CENTERS OF RESEARCH: HEMOSTATIC AND THROMBOTIC DISEASES NIH GUIDE, Volume 23, Number 13, April 1, 1994 RFA AVAILABLE: HL-94-013 P.T. National Heart, Lung, and Blood Institute Letter of Intent Receipt Date: May 31, 1994 Application Receipt Date: September 15, 1994 THIS IS A NOTICE OF AVAILABILITY OF A REQUEST FOR APPLICATIONS (RFA); IT IS ONLY AN ABSTRACT OF THE RFA. POTENTIAL APPLICANTS MUST REQUEST THE COMPLETE RFA, WHICH CONTAINS ESSENTIAL INFORMATION FOR THE PREPARATION OF THE APPLICATION, FROM THE CONTACT LISTED IN THE "INQUIRIES," BELOW. FAILURE TO FOLLOW THE INSTRUCTIONS IN THE COMPLETE RFA MAY RESULT IN AN INCOMPLETE APPLICATION, WHICH WILL BE RETURNED TO THE APPLICANT WITHOUT REVIEW. PURPOSE The objectives of the Specialized Centers of Research (SCOR) program in Hemostatic and Thrombotic Diseases are to improve the basic understanding of the processes involved in hemostasis and thrombosis and to encourage the application of this fundamental knowledge to clinical situations. This initiative emphasizes the use of new and innovative technology to provide better insight and develop treatment for thrombosis and related cardiovascular disorders that are the leading cause of death in the United States. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Specialized Centers of Research in Hemostatic and Thrombotic Diseases, is related to the priority area of blood diseases and resources. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by for-profit and non-profit domestic institutions, public and private, such as universities, colleges, hospitals, and laboratories. Awards will not be made to foreign institutions. However, under exceptional circumstances, a foreign component critical to a project may be included as a part of that project. Women and minority investigators are encouraged to apply. MECHANISM OF SUPPORT This RFA will use the National Heart, Lung, and Blood Institute (NHLBI) SCOR (P50) grant to support this research program. Responsibility for the planning, direction, and execution of the proposed project will be solely that of the applicant. All current policies and requirements that govern the research grant programs of the NIH will apply to grants awarded under this RFA. Basic and Clinical Research It is essential that all applications include both basic and clinical research projects. Interactions between basic and clinical scientists are expected to strengthen the research, enhance transfer of fundamental research findings to the clinical setting, and identify new research directions. Applications that include only basic or only clinical research will not be responsive to this RFA. In addition, clinical research projects focused on large epidemiologic studies or large clinical trials will be considered unresponsive to this RFA. FUNDS AVAILABLE Up to $1,125,000 in direct costs, not including indirect costs for collaborating institutions, in the first year with a maximum increase of no more than four percent in each additional year may be requested in each application. Award of grants pursuant to this RFA is contingent upon receipt of funds for this purpose. It is anticipated that at least two new SCOR grants will be funded. NHLBI's FY 1996 plans for this initiative include a maximum of $4.4 million. The specific amount to be funded will, however, depend on the merit and scope of the applications received and on the availability of funds. RESEARCH OBJECTIVES Background Thrombosis and related cardiovascular diseases are the leading cause of death in the US. The progress made in thrombosis research has revealed a complex and dynamic balance between the thrombotic and fibrinolytic systems. Major new advances have put us on the threshold of fundamental understanding of the cellular and surface processes involved in modulating thrombotic and fibrinolytic pathways. Understanding the biology of endothelial cells is still in its infancy and a deeper insight into this area may lead to major therapeutic advances. New understandings in molecular genetics is likely to make gene therapy of bleeding disorders a reality. Progress is being made in the knowledge of how megakaryocytes grow and differentiate and what controls platelet production. With identification of growth factors that control these processes, the day may not be too far away when circulating levels of platelets may be regulated and the devastating consequences of neonatal thrombocytopenia avoided. There is a need to continue this research progress and put special emphasis on applying these basic research accomplishments to clinical situations. The overall goal of this program is to support quality basic research, facilitate transfer of the basic knowledge to the bed side and stimulate clinical studies in hemostatic and thrombotic diseases. Such a program will require an intimate interface between basic and clinical research that cannot be accomplished by other means of support provided by NHLBI. It becomes essential then that all SCOR applications must contain major clinical components. Other factors such as research programs complementary to thrombosis area, institutional training programs, training experience of the SCOR director and other key staff will be considered important for the enrichment of the scientific environment under which mutual information exchange may flourish. Proposed Research The principal aim of this RFA is to encourage basic and clinical research towards the improvement of prevention/therapy of hemostatic and thrombotic diseases. Recent progress in the understanding of gene regulation and identification of anticoagulant factors make this an opportune time to encourage research in the following areas of emphasis: (1) risk factors for thrombosis; (2) influence of nutritional elements and environmental factors on hemostatic and thrombotic disease; (3) diagnosis, assay, and treatment for venous thrombosis; (4) regulation of adhesive proteins and processes: and (5) synthesis, catabolism and function of fibrinolytic proteins. The topics may address one or more than one area of emphasis. Applicants should also note that a SCOR program must meet the following criteria: (1) address areas of significant national need and clinical importance; (2) attract talented investigators who foster the development of a multidisciplinary and collaborative synergistic approach; (3) include both basic and clinical components; and, most importantly; (4) have the potential to accelerate the transfer of basic research to clinical application. Applicants may use their own imagination within the SCOR guidelines. STUDY POPULATIONS INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS Awards for research involving human subjects must follow the "NIH Guidelines On the Inclusion of Women and Minorities as Subjects in Clinical Research." See the RFA for details. LETTER OF INTENT Prospective applicants are asked to submit, by May 31, 1994, a letter of intent that includes a descriptive title of the proposed research; the name, address, and telephone number of the principal investigator; the identities of other key personnel and participating institutions; and the number and title of the RFA in response to which the application may be submitted. Although a letter of intent is not required, is not binding, and does not enter into the review of subsequent applications, the information that it contains is helpful in planning for the review of applications. It allows NHLBI staff to estimate the potential review workload and to avoid conflict of interest in the review. The letter of intent is to be sent to: Chief, Review Branch Division of Extramural Affairs National Heart, Lung and Blood Institute Westwood Building, Room 557A Bethesda, MD 20892 REVIEW CONSIDERATIONS Applications will be judged on the basis of the scientific and technical merit of the proposed research; the qualifications and research experience of the investigators; the collaborative interaction among basic and clinical research components; the adequacy of the environment; and the appropriateness of the budget. See RFA for additional information. APPLICATION PROCEDURES The research grant application form PHS 398 (rev. 9/91) is to be used in applying for these grants. These forms are available at most institutional offices of sponsored research and may be obtained from the Office of Grants Information, Division of Research Grants, National Institutes of Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone 301/594-7248. Applications must be received by September 15, 1994. INQUIRIES Written and telephone requests for the RFA and the opportunity to clarify issues or questions from potential applicants are welcome. Direct inquiries regarding scientific issues and requests for the RFA to: Pankaj Ganguly, Ph.D. Division of Blood Diseases and Resources National Heart, Lung and Blood Institute Federal Building, Room 5C14 Bethesda, MD 20892 Telephone: (301) 402-2237 FAX: (301) 496-9940 Direct inquiries regarding fiscal and administrative matters to: Ms. Jane Davis Division of Extramural Affairs National Heart, Lung and Blood Institute Westwood Building, Room 4A15C Bethesda, MD 20892 Telephone: (301) 594-7436 FAX: (301) 594-7492 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.839. Awards will be made under the authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirement of Executive Order 12372 or Health Systems Agency review. All current policies and requirements that govern the research grant programs of the NIH will apply to grants awarded under this RFA. $$R7 END ************************************************************ ONGOING PROGRAM ANNOUNCEMENTS $$P1 BEGIN PA-94-052 ************************************************ AGING AND BONE QUALITY NIH GUIDE, Volume 23, Number 13, April 1, 1994 PA NUMBER: PA-94-052 P.T. National Institute on Aging National Institute of Arthritis and Musculoskeletal and Skin Diseases PURPOSE The National Institute on Aging (NIA) and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) invite research applications to elucidate the nature and consequences of age-related changes in bone quality and the relationship of these changes to enhanced bone fragility and susceptibility to osteoporotic fractures. Factors that contribute to bone quality include architecture, density and mechanical strength. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This Program Announcement (PA), Aging and Bone Quality, addresses the priority area of osteoporosis. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by foreign and domestic, non-profit and for-profit organizations, private and public such as colleges, universities, laboratories, units of state and local governments, and eligible agencies of the Federal government. Foreign institutions are not eligible for First Independent Research Support and Transition (FIRST) awards (R29). Applications from minorities and women are encouraged. MECHANISM OF SUPPORT Support for this program will be by the research project grant (R01) and the FIRST (R29) award. RESEARCH OBJECTIVES Background The progressive loss of bone with age very commonly leads to osteoporosis, a condition characterized by increased skeletal fragility and susceptibility to fracture. Osteoporosis and its consequences are a significant cause of frailty, morbidity, and even mortality. However, while in older individuals reduced bone mass is important both in contributing to and predicting an enhanced risk of fracture, low bone mass alone is not a sufficient explanation for osteoporotic fractures. This is exemplified by the substantial overlap in bone density between normal individuals and patients who sustain hip and other osteoporotic fractures. A new perspective is needed that broadens the conceptual basis of skeletal integrity to include in addition to bone mass, qualitative factors that may impact on bone strength such as geometry, macro and micro-structural organization, distribution of material within bone, biochemical composition, and the burden of unrepaired microdamage. An NIA Workshop on Aging and Bone Quality, held September 3-4, 1992, underscored the need to study bone quality and identified promising new areas of research, which can be found in the workshop Proceedings in Calcified Tissue International, Supplement 1, (53), 1993. This PA reflects the priority areas that were identified at the workshop. This PA is directed towards: (1) stimulating research aimed at elucidating age-related mechanisms that influence the development and/or course of osteoporosis and (2) developing strategies aimed at preventing or lessening the burden of osteoporosis-related fractures in older individuals. Specifically, this PA seeks applications for basic and clinical research to identify and evaluate the effects of age on factors related to bone quality and/or strategies to modify the impact of these factors on skeletal fragility and increased fracture susceptibility. Topics of interest include, but are not limited to: o Age-related changes in architecture, mechanical properties, and strength of bone o Evaluation of changes in bone matrix and mineralization and their impact on strength and resistance to microdamage o Assessment of the consequences of age on the accumulation of cortical and trabecular microdamage and their relationship to bone strength and fracture biomechanics o Age-related changes in the detection of microdamage and activation, and initiation of the remodelling and repair processes in bone o Determination of age- and disease-related changes in biochemical, cellular, and structural factors affecting bone quality o Elucidation of the role and function of osteocytes and bone lining cells in bone metabolism o The nature of changes in osteocyte viability and function with age and the effect of these changes on the structural and mechanical properties of bone o Development of model systems that reflect normal physical and physiological aspects related to functional loading and responses to loading in aged bone o Development and application of techniques such as histomorphometry, ultrasound, NMR, and QCT to evaluate changes in architecture, bone strength and fracture susceptibility STUDY POPULATIONS INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS Awards for research involving human subjects must follow the "NIH Guidelines On the Inclusion of Women and Minorities as Subjects in Clinical Research." See the RFA for details. APPLICATION PROCEDURES Applications are to be submitted on the application form PHS 398 (rev. 9/91) available at most institutional offices of sponsored research and from the Office of Grants Information, Division of Research Grants, National Institutes of Health, 5333 Westbard Avenue, Room 449, Bethesda, MD 20892, telephone 301-594-7248. Applications will be accepted on the standard application receipt dates as indicated in the application kit. The program announcement title and number must be typed on line 2a of the face page. FIRST (R29) award applications must include at least three sealed letters of reference attached to the face page of the original application. FIRST award applications submitted without the required number of reference letters will be considered incomplete and will be returned without review. The completed original application and five legible copies must be sent or delivered to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** REVIEW CONSIDERATIONS Applications will be assigned on the basis of established PHS referral guidelines. Applications will be reviewed for scientific and technical merit in accordance with the standard NIH peer review procedures. Following scientific-technical review, applications recommended for further consideration will receive a second-level review by the appropriate national advisory council. AWARD CRITERIA Applications will compete for available funds on the basis of scientific merit, program balance among research areas of the announcement, and the availability of funds. INQUIRIES Written and telephone inquiries concerning this PA are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: Chhanda Dutta, Ph.D. Geriatrics Program National Institute on Aging $$XID NIHGUIDE 19940401 V23N13 P2O2 ************************************ Gateway Building, Suite 3E327 Bethesda, MD 20892 Telephone: (301) 496-1033 Joan A. McGowan, Ph.D. Bone Biology and Bone Diseases Program National Institute of Arthritis and Musculoskeletal and Skin Diseases Westwood Building, Room 403 Bethesda, MD 20892 Telephone: (301) 594-9957 Direct inquiries regarding fiscal matters to: Joanne Colbert Grants and Contracts Management Office National Institute on Aging Gateway Building, Room 2N212 Bethesda, MD 20892 Telephone: (301) 496-1472 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.866. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410), as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR Part 52 and 45 CFR Parts 74 and 92. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or to the Health Systems Agency review. Awards will be administered under PHS grants policy as stated in the PHS Grants policy statement, DHHS Publication NO. (OASH) 90-50,000, revised October 1, 1990. $$P1 END ************************************************************ ADDENDUM $$A1 BEGIN ********************************************************** GRANT WRITING WORKSHOP FOR NUTRITION FOR PROGRAM ANNOUNCEMENT PA-94- 033 NIH GUIDE, Volume 23, Number 13, April 1, 1994 P.T. 34; K.W. 0710095, 1014006 National Cancer Institute The following addendum is added to the notice that appeared in the NIH Guide for Grants and Contracts, Vol. 23, No. 11, March 18, 1994: "For persons who are unable to attend, a transcript of the meeting will be made available, and may be obtained by contacting: Dr. Jacqueline Whitted Division of Cancer Prevention and Control National Cancer Institute Executive Plaza North, Room 232 Bethesda, MD 20892 Telephone: (301) 496-8584 FAX: (301) 496-8675 $$A1 END ************************************************************ From owner-sci-resources@net.bio.net Tue Apr 05 23:00:00 1994 Path: biosci!biosci!not-for-mail From: Dave Kristofferson Newsgroups: bionet.sci-resources Subject: NIH GUIDE - RFA HL-94-012 - V23(13) 04/01/94 Date: 5 Apr 1994 17:02:02 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 699 Approved: biosci-moderator@net.bio.net Distribution: bionet Message-ID: <2nsu5q$42q@net.bio.net> NNTP-Posting-Host: net.bio.net $$XID RFA HL94012 HL-94-012 P1O1 *************************************** SPECIALIZED CENTERS OF RESEARCH: TRANSFUSION BIOLOGY AND MEDICINE NIH GUIDE, Volume 23, Number 13, April 1, 1994 RFA: HL-94-012 P.T. National Heart, Lung, and Blood Institute Letter of Intent Receipt Date: May 31, 1994 Application Receipt Date: September 15, 1994 PURPOSE The objectives of the Specialized Centers of Research (SCOR) program in Transfusion Biology and Medicine are to improve the safety and efficacy of blood and blood components, define the indications for their use, evaluate and possibly modify immunological responsiveness following their administration, and develop and evaluate alternative treatment strategies that substitute for certain of their functions or stimulate their endogenous production so as to reduce transfusion needs. This initiative also encourages the use of new and innovative technologies to pursue fundamental research studies in transfusion biology and clinical investigations in transfusion medicine. The goals of this program are to understand better the basic biology of transfusion; make optimal use of blood, blood components, and plasma protein derivatives in specific replacement therapy; improve transfusion practice; and perform basic and applied research on blood substitutes. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This Request for Applications (RFA), Specialized Centers of Research in Transfusion Biology and Medicine, is related to the priority area of maternal and infant health. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by for-profit and non-profit domestic institutions, public and private, such as universities, colleges, hospitals, and laboratories. This RFA is intended to support SCOR grants for basic and clinical investigations. Therefore, applications that include only basic or only clinical research will not be responsive to this RFA. In addition, clinical research projects focused on large epidemiologic studies or large clinical trials will be considered unresponsive to this RFA. Awards will not be made to foreign institutions. However, under exceptional circumstances, a foreign component critical to a project may be included as a part of that project. Women and minority investigators are encouraged to apply. MECHANISM OF SUPPORT This RFA will use the National Heart, Lung, and Blood Institute (NHLBI) SCOR (P50) grant to support this research program. Responsibility for the planning, direction, and execution of the proposed project will be solely that of the applicant. All current policies and requirements that govern the research grant programs of the NIH will apply to grants awarded under this RFA. Basic and Clinical Research The overall concept of a SCOR program focuses on scientific issues related to diseases and therapies relevant to the mission of the NHLBI. It is essential, therefore, that all applications include both basic and clinical research. Interactions between basic and clinical scientists are expected to strengthen the research, enhance transfer of fundamental research findings to the clinical setting, and identify new research directions. Plans for transfer of findings from basic to clinical studies should be described. Each SCOR grant application and award must include research involving human patients/subjects. Support may be provided for human biomedical and behavioral studies of etiology, pathogenesis, prevention and prevention strategies, diagnostic approaches, and treatment of diseases, disorders, or conditions. Small population-based studies, where the research can be completed within five years, may also be proposed. In addition, basic research projects must be included that relate to the clinical focus. A SCOR may also contain one or more core units that support the research projects. The Principal Investigator should be an established research scientist with the ability to ensure quality control and the experience to administer effectively and integrate all components of the program. A minimum time commitment of 25 percent is expected for this individual. The Principal Investigator must also be the project leader of one of the component research projects. Project leaders must agree to commit at least 20 percent effort to each project for which they are responsible. Applications from institutions that have a General Clinical Research Center (GCRC) funded by the NIH, National Center for Research Resources may wish to identify the GCRC as a resource for conducting the proposed research. If so, a letter of agreement from the GCRC program director/principal investigator could be included with the application. Length of SCOR Programs Each NHLBI SCOR program is limited to 10 years of support. Exceptions to this policy will be made only if a thorough evaluation of needs and opportunities, conducted by a committee composed of non-federal experts, determines that there are extraordinarily important reasons to continue a specific SCOR program. Thus, under this policy, a given SCOR grant is awarded for a five-year project period following an open competition. If the one five-year competing renewal that is permitted is awarded, a total of no more than 10 years of support is possible, unless the SCOR program is recommended for extension. The NHLBI comprehensive evaluation of the Transfusion Biology and Medicine SCOR program will be conducted during the second project period according to the following timetable: Program Announced: FY 1994 Project Period (First Competition): FY 1996 to FY FY 2000 Program Reannounced: FY 1999 Project Period: FY 2001 to FY 2005 (Second Competition) Letter to SCOR Directors Regarding SCOR Evaluation: FY 2002 (midway in year 02 of 2nd project period) SCOR Evaluation Meeting: FY 2003 (late in year 02 of 2nd project period) Notification of SCOR Directors Regarding NHLBI Decision: FY 2003 (midway in year 03 of 2nd project period) Number of Applications The NHLBI does not limit the number of SCOR applications in a given SCOR program from one institution provided there is a different SCOR Principal Investigator for each application and each application is self-contained and independent of the other(s). This arrangement does not preclude cooperation planned or possible among participants of SCORs after awards are made. Scientific overlap among applications will not be accepted. If more than one application is envisioned from an institution, the institution is encouraged to discuss its plans in advance with the NHLBI SCOR program administrator. FUNDS AVAILABLE Applicants may request up to $1,125,000 in direct costs, not including indirect costs for collaborating institutions, in the first year with a maximum increase of no more than four percent in each additional year requested in the application. Award of grants pursuant to this RFA is contingent upon receipt of funds for this purpose. It is anticipated that at least two SCOR grants will be funded. NHLBI's FY 1996 plans for this initiative include a maximum of $4.4 million. The specific amount to be funded will, however, depend on the merit and scope of the applications received and on the availability of funds. Equipment is included in the budget limitation. However, requests for expensive special equipment that cause an application to exceed this limit may be permitted on a case-by-case basis following staff consultation. Such equipment requires in-depth justification. Final decisions will depend on the nature of the justification and the fiscal situation of the NHLBI. Consortium Arrangements If a grant application includes research activities that involve institutions other than the grantee institution, the program is considered a consortium effort. Such activities may be included in a SCOR grant application, but it is imperative that a consortium application be prepared so that the programmatic, fiscal, and administrative considerations are fully explained. The published policy governing consortia is available in the business offices of institutions that are eligible to receive Federal grants-in-aid. Consult the latest published policy governing consortia before developing the application. If clarification of the policy is needed, contact Ms. Jane Davis, Grants Operations Branch, NHLBI, 301-594-7436. Applicants of SCOR grants should exercise great diligence in preserving the interactions of the participants and the integration of the consortium project(s) with those of the parent institution, because synergism and cohesiveness can be diminished when projects are located outside of the group at the parent institution. Indirect costs paid as part of a consortium agreement are excluded from the limit on the amount of direct costs that can be requested. RESEARCH OBJECTIVES Background During the past decade, significant scientific advances have been made in Transfusion Medicine that have improved the safety and quality of blood, blood components, and plasma derivatives and changed transfusion practices. Advances have been made in detecting evidence for viral pathogens such as HIV-1, HIV-2, HTLV-I/HTLV-II and hepatitis C in donated blood, thus preventing such agents from entering the blood supply. Moreover, procedures have been developed to inactivate viruses in plasma derivatives and soon in plasma itself. Improved apheresis technologies have been developed that permit more efficient collection and manipulation of blood components and bone marrow. Investigators have described properties of newly developed plasma derivatives. Techniques have been developed that may lead to the use of stem cells from umbilical cord blood for bone marrow transplantation. As a result, the importance of blood transfusion has been greatly expanded through the use of components and derivatives in increasingly specialized and effective forms of therapy. The use of blood and blood components continues to increase. Improved patient care, including aggressive cancer chemotherapy programs, bone marrow transplantation, and sophisticated cardiac surgery procedures have contributed heavily to this growth, which is expected to continue into the future. Consequently, the implementation of research programs to determine the optimal use of this valuable resource is important and timely. Blood centers, as well as medical centers with large transfusion services, provide an important environment for research in transfusion medicine. These centers also provide a variety of educational opportunities aimed at several groups, both within and outside the special blood bank community, including laboratory technicians, undergraduate and graduate students, and practicing physicians. The SCOR mechanism is a very important and vital approach to address issues and problems confronting transfusion medicine today. Some of the advantages of this mechanism are: o A SCOR brings together multidisciplinary groups of investigators with valuable expertise to transfusion medicine. o With its multidisciplinary mix of basic, applied, and clinical research, a SCOR offers investigators invaluable resources for research through coordinated interactions. o The information that emerges from the research program of a SCOR may be useful in addressing important national policy issues in transfusion medicine. In the past, the SCOR program made important contributions to the NHLBI and other federal agencies. This involvement was particularly important during the turbulent times brought about by the AIDS epidemic. o A SCOR also addresses difficult clinical questions and provides the research needed to address related policy questions. The Transfusion Medicine SCOR program, like the subspecialty that it serves, is in an early, but continually evolving, state of development. Nevertheless, in the brief history of the program there have been major accomplishments in basic and clinical research that include: o Discovery of gp120 in the envelope of HIV-1 and recognition of its importance for use as an antigen to detect HIV-1 antibody in blood. o Discovery of HIV-1 and HIV-2 specific regulatory proteins and demonstration that they provide a means of distinguishing between the two viruses. o Initial development of assays to detect HIV-2 by serological means. o Recognition of the importance of the Tax gene product of HTLV-I/HTLV-II for screening blood. o Discovery of a pronounced downturn in national rates of blood collection and transfusion of red blood cells following proof that HIV is transmissible by transfusion. o Discovery of significant differences across hospitals in transfusion practice in patients undergoing the same surgical procedures. o Recognition of the importance of type specific screening of HTLV-II for the blood supply. o Use of soluble HLA Class I antigens to induce tolerance. o Performance of some feasibility studies in unrelated bone marrow transplantation. o Characterization of transfusion-related tolerance induction for solid organ transplantation. o Development of practical management strategies for platelet transfusion therapy. Since inception of the Transfusion Medicine SCOR program eight years ago, a large proportion of studies in this program have dealt with transfusion-transmitted infectious diseases, particularly AIDS. This focus on infectious disease was in part a response to the recognition that HIV-1 could be transmitted by blood transfusion. The multidisciplinary configuration of the SCOR program was ideally suited to meet the challenge of transfusion-associated AIDS. As a consequence, significant contributions were made in the understanding of HIV-1, HIV-2 and other human retroviruses. The knowledge gained from the Transfusion Medicine SCOR program contributed significantly, for example, in the selection, design and development of specific assays to detect the presence of human retroviruses in blood donors. With implementation of donor screening procedures that virtually eliminate HIV-1 and significantly reduce the likelihood of other transfusion-transmitted viruses from entering the blood supply, the NHLBI is now redirecting its SCOR program to address other important areas of scientific need and opportunity in Transfusion Biology and Medicine. Proposed Research Five areas of special emphasis have been identified that are essential for the optimal use and improvement of transfusion therapy. Recent progress in the understanding in such areas as immune regulation and hematopoiesis make this an opportune time to encourage research in the following areas of emphasis. Immunomodulatory Aspects of Transfusion The immune system occupies a central role in the safety and efficacy of transfusion therapy. One of the major problems in transfusion therapy is alloimmunization. In some situations, the occurrence may be of little consequence, but as a general problem, alloimmunization is of great importance as it limits the effectiveness of transfusions and in some cases results in death of the patient. Investigators in this SCOR program are encouraged to pursue studies that focus on the mechanisms, prevention, and management of alloimmunization to transfused blood and blood components. One approach could include strategies for rendering transfused products such as platelets nonimmunogenic by removing, altering, or masking surface antigens or interfering with immune "trigger cells." More information is needed about factors that determine immune responses in different individuals and the ways of predicting patients' potential responses. It is also important to improve our understanding of possible deleterious immunologic effects of transfusions such as enhancement of tumor growth and tumor recurrence as well as increasing susceptibility to infections. Studies on potential therapeutic applications of immune modulation might be pursued such as the use of intravenous immune globulins, staph protein A columns, photopheresis, and soluble class I and class II HLA antigens. Development of Novel Cell Therapies and Cytokine Therapies Recent developments in the understanding of hematopoiesis and stem cell biology, the identification of hematopoietic growth factors and cytokines, and cell culture technology hold promise for the creation of novel cellular components and transfusion therapies. Studies are needed on the identification, collection, purification, and preservation of hematopoietic stem cells for use in transplantation. Studies on the in vitro expansion of hematopoietic stem cells for later use in vivo are also encouraged. Significant advances have been made that create realistic prospects for the establishment of in vitro culture systems for production of stem cells for transplantation and for the production of specific cell populations for transfusion therapy. Studies are encouraged to further the understanding of the in vitro requirements for such culture systems including the use of cytokines. In addition to the use of cytokines to support the in vitro expansion of cells, studies are also needed to determine the optimal use of cytokines in vivo to reduce transfusion needs. Studies might address the identification of those disease states where cytokine therapy might be of use. Studies are needed on the dose and timing of cytokine therapy. Research studies on the regulation of endogenous cytokine production are important and could eventually lead to clinical therapies. Structure/Function Relationships of Human Blood Cell Surface Antigens Studies are needed to better understand the relation of structure to function in human blood cells, particularly red blood cells and platelets. There is a need for studies on the characterization and biological significance of blood cell surface antigens, particularly as they relate to the structural integrity of the cells, to specific cell functions, and to specific disease processes. Until recently, the major reasons for identifying blood group antigens and antibodies has been their importance in assuring safe and effective blood transfusions. In recent years, however, clinical information regarding the relation of blood cell antigens to disease has accumulated, as has knowledge of blood cell membrane structure and function. Platelet antigens are known to be associated with functional glycoproteins on platelet membranes and platelet antibodies have been shown to affect platelet function. Similar studies are needed to determine what role antibodies may play in altering red blood cell function. Basic research studies might also be pursued into understanding membrane biology and signaling in blood cells. In the area of applied research, more studies are needed on the improvement in the quality of cellular products used in transfusion therapy. With the recent emergence of new technologies to study cellular membranes and other cellular elements, this is an opportune time to pursue studies to improve the quality of platelet concentrates used for transfusion. Blood Substitutes Research on oxygen-carrying red cell substitutes could lead to the development of products that provide short or even possibly long term support for anemic patients with the advantages of being universally compatible, pathogen free, and without the requirement for cross-matching. They would ideally have a long shelf-life and offer convenient storage. There are currently several Phase I human safety trials of artificial oxygen carriers in various stages of study. The results reported thus far, have been disappointing as unexpected toxicities have been observed. Studies are needed to understand the mechanisms of toxicity of hemoglobin-based oxygen carriers. Projects might address the apparent vasoactivity of these preparations. Animal models or in need to be delineated. Studies on the efficacy of artificial oxygen carriers also need to be conducted under the experimental conditions that reflect the intended clinical use. Of particular importance are the function of artificial oxygen carriers in the presence of red cells; the measurement of tissue and organ function as an indication of efficacy; and the comparison of the efficacy of artificial oxygen carriers with that of red cells. Indications for Red Blood Cell or Platelet Transfusion Despite the obvious advantages of blood transfusion, there is concern that blood components such as red blood cells and platelets are at times given to patients who do not really need them, are given too frequently to patients who do need them, and occasionally, either are not given or are given in insufficient quantities when treatment is urgently required. Clinical decisions regarding red blood cell and platelet transfusions are hampered by a general lack of well designed clinical studies, by imprecise methods of evaluating clinical need and by uncertain methods for measuring effects. The time-honored and useful measurements of hemoglobin concentration and hematocrit are clearly not sufficient, by themselves, for many patients much of the time. Research studies are clearly needed to improve knowledge in these areas. Studies might focus on the detection or development of predictors that better define the need for red blood cell transfusion. The identification of organs that are specifically at risk during acute anemia and the development of clinical monitors that measure the state of perfusion and the presence of cellular hypoxia in those organs that are specifically sensitive to low hemoglobin values or a combination of low Hb and low perfusion are promising approaches that could be pursued. Studies are also needed to determine the appropriate indications for platelet transfusions. The platelet levels that predispose thrombocytopenic patients to hemorrhage and the efficacy of therapeutic modalities other than transfusion are not well understood and require investigation. The development of a practical test that predicts the likelihood of clinically significant platelet-related bleeding would be extremely useful. An area of special interest to the NHLBI is neonatal transfusion therapy. Dramatic advances in the care of infants of low to extremely low birth weight have resulted in survival beyond the immediate intrapartum period. Current practice often includes transfusions with red blood cells as part of the therapy for most of these infants. However, adequacy of red blood cell transfusion in the premature infant is most often assessed by measuring hemoglobin and hematocrit, two parameters that, as in adults, have limited correlation with both the need to transfuse as well as transfusion outcome. Research is needed to establish quantitative, clinically useful criteria to be used in addition to or instead of hemoglobin and hematocrit measurements in determining when to begin and end blood transfusions in newborns. There is a need for new, innovative methods to assess oxygen delivery in the newborn. Furthermore, studies to determine transfusion outcomes in this population are also needed. The different research topics and approaches described in the five areas of emphasis are intended to provide potential applicants with examples of the types of topics that are of interest to the NHLBI and worthy of pursuit. These examples, however, are not meant to be all inclusive. Investigators are encouraged to consider pursuing other important and innovative scientific topics as well. It should be emphasized, however, that the topics chosen must relate directly to the five areas of emphasis identified in this initiative. Furthermore, the topics may address one or more than one area of emphasis. For example, it would be appropriate for a SCOR applicant to propose projects that address research issues pertaining to one area of interest such as structure/function relationships of human blood cell surface antigens or a combination such as structure/function relationships of human blood cell surface antigens and immunomodulatory aspects of transfusion. Applicants should also note that a SCOR program must meet the following criteria: (1) address areas of significant national need and clinical importance; (2) attract talented investigators who foster the development of a multidisciplinary and collaborative synergistic approach; (3) include both basic and clinical components; and, most importantly; (4) have the potential to accelerate the transfer of basic research to clinical application. Applicants are requested to contact the project officer of this initiative prior to preparing a SCOR application to make certain that their proposed program is compatible with the objectives of this solicitation. The major emphasis of this SCOR program is on basic, applied and clinical research in transfusion biology and medicine, the nature of which will depend upon the interests and areas of expertise of its investigators, as well as on the physical resources and population available. However, each institution requesting SCOR support should have a basic range of competence and potential that will enable it to develop a program addressing the objectives and goals of this initiative. SCORs should also provide a challenging environment for attracting talented young scientists into biomedical research and offering opportunities for career development. STUDY POPULATIONS INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their subpopulations must be included in all NIH supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This new policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43) and supersedes and strengthens the previous policies (Concerning the Inclusion of Women in Study Populations, and Concerning the Inclusion of Minorities in Study Populations), which have been in effect since 1990. The new policy contains some provisions that are substantially different from the 1990 policies. All investigators proposing research involving human subjects should read the "NIH Guidelines For Inclusion of Women and Minorities as Subjects in Clinical Research," which have been published in the Federal Register of March 9, 1994 (FR 59 11146-11151) and reprinted in the NIH Guide for Grants and Contracts, Volume 23, Number 11, March 18, 1994. Investigators also may obtain copies of the policy from the program staff listed under INQUIRIES. Program staff may also provide additional relevant information concerning the policy. (NOTE: When the proposed study or studies in the RFA or PA involves a gender specific study or a single or limited number of minority population groups, this should also be stated to inform potential applicants and reviewers.) LETTER OF INTENT Prospective applicants are asked to submit, by May 31, 1994, a letter of intent that includes a descriptive title of the proposed research; the name, address, and telephone number of the principal investigator; the identities of other key personnel and participating institutions; and the number and title of the RFA in response to which the application may be submitted. Although a letter of intent is not required, is not binding, and does not enter into the review of subsequent applications, the information that it contains is helpful in planning for the review of applications. It allows NHLBI staff to estimate the potential review workload and to avoid conflict of interest in the review. The letter of intent is to be sent to: Chief, Review Branch Division of Extramural Affairs National Heart, Lung, and Blood Institute Westwood Building, Room 557A Bethesda, MD 20892 APPLICATION PROCEDURES The research grant application form PHS 398 (rev. 9/91) is to be used in applying for these grants. These forms are available at most institutional offices of sponsored research and may be obtained from the Office of Grants Information, Division of Research Grants, National Institutes of Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone 301/594-7248. The RFA label available in the PHS 398 application form must be affixed to the bottom of the face page of the application. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review. In addition, to identify the application as a response to this RFA, check "YES", enter the title "Specialized Centers of Research in Transfusion Biology and Medicine", and the RFA number HL-94-012 on line 2a of the face page of the application. Send or deliver a signed, typewritten original of the application, including the checklist, and three signed photocopies, in one package to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** Send two additional copies of the application to the Chief, Review Branch at the address listed under LETTER OF INTENT. It is important to send these two copies at the same time as the original and three copies are sent to the Division of Research Grants (DRG), otherwise the NHLBI cannot guarantee that the application will be reviewed in competition for this RFA. Applications must be received by September 15, 1994. If an application is received after that date, it will be returned to the applicant. DRG will not accept any application in response to this RFA that is essentially the same as one currently pending initial review, unless the applicant withdraws the pending application. DRG will not accept any application that is essentially the same as one already reviewed. This does not preclude the submission of substantial revisions of applications already reviewed, but such applications must include an introduction addressing the previous critique. REVIEW CONSIDERATIONS Upon receipt, applications will be reviewed by National Institutes of Health (NIH) staff for completeness and responsiveness. Incomplete applications or applications deemed not responsive to the RFA will be returned to the applicant without further consideration. Those applications that are complete and responsive will be evaluated for scientific and technical merit by an appropriate peer review group convened by the NHLBI. Crucial to the initial scientific review will be a triage process that will eliminate all applications that are deemed not scientifically competitive within the goals and criteria of the RFA. The second level of review will be provided by the National Heart, Lung, and Blood Advisory Council. If, through peer review, this project is not recommended for further consideration, the overall SCOR application will not be considered further. If this project is judged by peer review to be of low scientific merit, it will markedly reduce the overall scientific merit ranking assigned to the entire application by the review committee. Factors to be considered in the evaluation of each application will be similar to those used in review of traditional research grant applications and, in addition, will include overall proposed interactions among basic and clinical research projects. Major factors to be considered in the evaluation of applications include: o Scientific merit of the proposed basic and clinical research projects including significance, importance, and appropriateness of the theme; innovation, originality, and feasibility of the approach; and adequacy of the experimental design. o Leadership, scientific stature, and commitment of the program director; competence of the investigators to accomplish the proposed research goals and their time commitment to the program; and the feasibility and strength of consortium arrangements. o Collaborative interaction among basic and clinical research components, the balance between them, and plans for transfer of potential findings from basic to clinical studies. o Adequacy of the environment for performance of the proposed research including clinical populations and/or specimens; laboratory facilities; proposed instrumentation; quality controls; administrative structure; institutional commitment; and, when needed, data management systems. o Appropriateness of the budget for the proposed program. INQUIRIES Written and telephone inquiries concerning this RFA are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding scientific issues to: George J. Nemo, Ph.D. Division of Blood Diseases and Resources National Heart, Lung, and Blood Institute Federal Building, Room 504 Bethesda, MD 20892 Telephone: (301) 496-1537 FAX: (301) 402-4843 Direct inquiries regarding fiscal and administrative matters to: Ms. Jane Davis Division of Extramural Affairs National Heart, Lung, and Blood Institute Westwood Building, Room 4A15C Bethesda, MD 20892 Telephone: (301) 594-7436 FAX: (301) 594-7492 AUTHORITY AND REGULATIONS The programs of the Division of Blood Diseases and Resources, NHLBI are described in the Catalog of Federal Domestic Assistance No. 93.839. Awards will be made under the authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirement of Executive Order 12372 or Health Systems Agency review. From owner-sci-resources@net.bio.net Tue Apr 05 23:00:00 1994 Path: biosci!biosci!not-for-mail From: Dave Kristofferson Newsgroups: bionet.sci-resources Subject: NIH GUIDE - RFA AR-94-005 - V23(13) 04/01/94 Date: 5 Apr 1994 17:02:20 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 419 Approved: biosci-moderator@net.bio.net Distribution: bionet Message-ID: <2nsu6c$43t@net.bio.net> NNTP-Posting-Host: net.bio.net $$XID RFA AR94005 AR-94-005 P1O1 *************************************** BASIC OSTEOPOROSIS NEW EXPERIMENTAL STRATEGIES NIH GUIDE, Volume 23, Number 13, April 1, 1994 RFA: AR-94-005 P.T. National Institute of Arthritis and Musculoskeletal and Skin Diseases National Institute of Diabetes and Digestive and Kidney Diseases National Institute on Aging Letter of Intent Receipt Date: June 28, 1994 Application Receipt Date: July 26, 1994 PURPOSE The Bone Biology and Bone Diseases Branch of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the Bone and Mineral Research Program of the Endocrinology Research Section of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and the Geriatrics and Biology of Aging Programs of the National Institute on Aging (NIA) invite investigator-initiated research project grant applications to encourage and facilitate research projects designed to develop promising basic cellular, molecular, physiological, and genetic approaches to osteoporosis. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This Request for Applications (RFA), Basic Osteoporosis New Experimental Strategies, is related to the priority areas of diabetes and chronic disabling conditions and older adults and preventive services. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic and foreign for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal government. Applications may be submitted by single institutions and by a consortia of institutions. Foreign institutions are not eligible for First Independent Research and Support and Transition (FIRST) (R29) awards. Applications from minority individuals and women are encouraged. MECHANISM OF SUPPORT Support for this program will be through investigator-initiated research grant applications (R01) and FIRST (R29) awards. This RFA is a one-time solicitation for fiscal year 1995. However, the NIAMS, NIDDK, and NIA may reissue the RFA in future years. If there is a continuing program need, the NIAMS, NIDDK, and NIA will invite recipients of awards under this RFA to submit competitive continuation applications. Responsibility for planning and implementation of the proposed project will be solely that of the applicant. The total project period for R01 applications submitted in response to the present RFA may not exceed four years. FIRST awards must be for five years. The anticipated award date is April 1, 1995. FUNDS AVAILABLE Approximately $2,000,000 in total costs per year for four years will be committed by the NIAMS to fund applications submitted in response to this RFA. An additional $500,000 will be committed by the NIDDK, and an additional $600,000 by the NIA. This funding level is dependent on the receipt of a sufficient number of applications of high scientific merit. The direct cost of each R01 project is limited to $160,000 for the first year and R29s are limited to $70,000. Thus it is anticipated that a total of 12 to 14 projects will be funded in FY 95. Although this program is provided for in the financial plans of the NIAMS, NIDDK, and NIA, the award of grants, as well as the final amounts awarded, will be contingent upon the availability of funds for this purpose. Applicants from institutions that have a General Clinical Research Center (GCRC) funded by the NIH National Center for Research Resources may wish to identify the GCRC as a resource for conducting the proposed research. If so, a letter of agreement from either the GCRC program director or principal investigator should be included with the application. RESEARCH OBJECTIVES Background Much work remains to be done in order to counter the disabling, costly consequences of osteoporosis. Means of targeting nutritional and pharmacological preventive strategies to individuals most at risk for bone loss are needed in order to reduce the incidence of fractures and the attendant costs to society. Alternatives to the available preventive drug therapies are needed in order to extend their utility to the largest possible number of people. Effective approaches to the treatment of established osteoporosis are urgently needed. Such new therapeutic approaches are most likely to arise from improved understanding of the basic biology of bone growth and maintenance. Recent scientific and technological developments have markedly expanded opportunities for understanding the molecular and genetic basis of osteoporosis. Details are beginning to emerge of the complex network of signalling mechanisms that control bone growth and maintain skeletal integrity. Specific probes have made it possible to identify new molecules responsible for the local and systemic regulation of bone cell function, as well as the cell surface molecules and linked signal transduction pathways that mediate their effects. In particular, the complex relationship between the bone microenvironment and the immune system demands attention. The identification, mapping, and structural analysis of genes with crucial functions in the regulation of bone are increasingly feasible research goals. The use of genetically manipulated animals allows investigators to test the effects of specific gene inactivation or over-expression. The identification of genetic variations in the human population that underlie different vulnerabilities to bone loss is made possible by the increasing knowledge of the human genome and advancing molecular screening technology. In order to capitalize on these opportunities, it is necessary to integrate biological insights and methodologies from a broad range of specialties. The overall goal of the Basic Osteoporosis New Experimental Strategies (BONES) initiative is to encourage and support new basic research in the areas of bone structure, formation, remodeling, and repair. This initiative is designed to (1) encourage established bone biology investigators to address osteoporosis-related problems with novel approaches and the most powerful methodologies available; (2) increase the pool of investigators working in osteoporosis-related basic science areas by drawing researchers from genetics, cell and molecular biology, and structural chemistry into bone research; and (3) foster the development of interactions between laboratories originating in different disciplines. Research Goals and Scope Some examples of research areas in which applications would be considered responsive to this RFA include, but are not limited to: o Mechanisms of action of growth factors, cytokines, bone inductive factors, and other regulators of bone growth and remodeling; o Genes and gene products with critical roles in bone growth and remodeling; o Mechanisms of action of estrogens, androgens, and glucocorticoids on bone; o Origins and lineages of osteoblasts, osteoclasts, and osteocytes: nature of precursor cells; control of activation, proliferation, and differentiation; role of marrow stromal stem cells; o Mechanisms of regulation of bone growth and remodeling by physical forces: loading stress, exercise, immobilization, and microgravity; o Biochemical and genetic markers of osteoporosis; o Biomechanical and non-invasive assessment of bone quality and architecture; o Influence of extracellular matrix composition and architecture on bone; growth and remodeling in normal and pathologic conditions; o Relationship between bone formation and vascularization in normal bone growth and fracture repair; o Cell and animal models for osteoporosis; o Effects of age and age-related changes on the level and action of hormones, growth factors, cytokines, and other osteotropic/osteogenic factors, and the impact and underlying mechanisms of such changes on bone remodeling and repair; o Elucidation of the nature and underlying mechanisms of age-related changes in the activation, proliferation and differentiation of bone cells and bone cell precursors; and o Determination of the mechanisms and consequences of age-related changes in bone vascularization and extracellular matrix on bone remodeling and bone architecture. Investigators are not limited to the above examples of research areas, and are encouraged to propose other approaches that are appropriate to the R01 and R29 mechanisms and the requirements of this RFA. STUDY POPULATIONS INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their subpopulations must be included in all NIH supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This new policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43) and supersedes and strengthens the previous policies (Concerning the Inclusion of Women in Study Populations, and Concerning the Inclusion of Minorities in Study Populations), which have been in effect since 1990. The new policy contains some provisions that are substantially different from the 1990 policies. All investigators proposing research involving human subjects should read the "NIH Guidelines For Inclusion of Women and Minorities as Subjects in Clinical Research," which have been published in the Federal Register of March 9, 1994 (FR 59 11146-11151) and reprinted in the NIH Guide for Grants and Contracts, Volume 23, Number 11, March 18, 1994. Investigators also may obtain copies of the policy from the program staff listed under INQUIRIES. Program staff may also provide additional relevant information concerning the policy. (NOTE: When the proposed study or studies in the RFA or PA involves a gender specific study or a single or limited number of minority population groups, this should also be stated to inform potential applicants and reviewers.) LETTER OF INTENT Prospective applicants are asked to submit, by June 28, 1994, a letter of intent that includes a descriptive title of the proposed research, the name, address, and telephone number of the Principal Investigator, the identities of other key personnel and participating institutions, and the number and title of the RFA in response to which the application may be submitted. Although a letter of intent is not required, is not binding, and does not enter into the review of subsequent applications, the information that it contains allows NIH staff to estimate the potential review workload and to avoid conflict of interest in the review. The letter of intent is to be sent to Dr. William Sharrock at the address listed under INQUIRIES. APPLICATION PROCEDURES The research grant application form PHS 398 (rev. 9/91) is to be used in applying for this RFA. These forms are available at most institutional offices of sponsored research; from the Office of Grants Information, Division of Research Grants, National Institutes of Health, 5333 Westbard Avenue, Room 449, Bethesda, MD 20892, telephone 301-594-7248; and from the NIH program staff listed under INQUIRIES. Applications for the FIRST Award (R29) must include at least three sealed letters of reference attached to the face page of the original application. FIRST Award (R29) applications submitted without the required number of reference letters will be considered incomplete and will be returned without review. The RFA label available in the PHS 398 (rev. 9/91) application form must be affixed to the bottom of the face page of the application. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review. In addition, the RFA title and number must be typed on line 2a of the face page of the application form and the YES box must be marked. Submit a signed, typewritten original of the application, including the Checklist, and three signed photocopies, in one package to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** At the time of submission, two additional copies of the application must also be sent to: Dr. Tommy Broadwater Review Branch National Institute of Arthritis and Musculoskeletal and Skin Diseases Westwood Building, Room 406 Bethesda, MD 20892 Telephone: (301) 594-9979 FAX: (301) 594-9673 Applications must be received by July 26, 1994. If an application is received after that date, it will be returned to the applicant without review. The Division of Research Grants (DRG) will not accept any application in response to this announcement that is essentially the same as one currently pending initial review, unless the applicant withdraws the pending application. The DRG will not accept any application that is essentially the same as one already reviewed. This does not preclude the submission of substantial revisions of applications already reviewed, but such applications must include an introduction addressing the previous critique. REVIEW CONSIDERATIONS Upon receipt, applications will be reviewed for completeness by the DRG and responsiveness by the NIAMS. Incomplete applications will be returned to the applicant without further consideration. If the application is not responsive to the RFA, NIAMS staff will contact the applicant to determine whether to return the application to the applicant or submit it for review in competition with unsolicited applications at the next review cycle. Applications may be triaged by an NIAMS peer review group on the basis of relative competitiveness. The NIH will withdraw from further competition those applications judged to be non-competitive for award and notify the applicant Principal Investigator and institutional official. Those applications judged to be competitive will undergo further scientific merit review. Those applications that are complete and responsive will be evaluated in accordance with the criteria stated below for scientific/technical merit by an appropriate peer review group convened by the NIAMS. The second level of review will be provided by the NIAMS, NIDDK, and NIA advisory councils. Review criteria for RFAs are generally the same as those for unsolicited research grant applications. o extent to which the proposed research addresses the goals of the RFA; o scientific, technical, or medical significance and originality of proposed research; o appropriateness and adequacy of the experimental approach and methodology proposed to carry out the research; o qualifications and research experience of the Principal Investigator and staff, particularly, but not exclusively, in the area of the proposed research; o adequacy of plans for overall collaboration; o availability of the resources necessary to perform the research; o adequacy of the mechanisms for quality control, study monitoring, data management and reporting and data analysis; o adequacy of provisions for the protection of human subjects; o adequacy of the plans for inclusion of females and minorities; and o appropriateness of the proposed budget and duration in relation to the proposed research; AWARD CRITERIA The anticipated date of award is April 1, 1995. In addition to the technical merit of the application as reflected in the priority score, the NIAMS, NIDDK, and NIA will consider how well the applicant institution meets the goals and objectives of the program as described in the RFA, availability of resources and/or study populations. INQUIRIES Written and telephone inquiries concerning this RFA are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: William Sharrock, Ph.D. Bone Biology and Bone Diseases Branch National Institute of Arthritis and Musculoskeletal and Skin Diseases Westwood Building, Room 403 Bethesda, MD 20892 Telephone: (301) 594-9975 FAX: (301) 594-9673 Ronald Margolis, Ph.D. Endocrinology Research Section National Institute of Diabetes and Digestive and Kidney Diseases Westwood Building, Room 621 Bethesda, MD 20892 Telephone: (301) 594-7549 FAX: (301) 594-9011 Sherry Sherman, Ph.D. Geriatrics Program National Institute on Aging Gateway Building, Suite 2C218 7201 Wisconsin Avenue Bethesda, MD 20892 Telephone: (301) 496-932 FAX: (301) 402-2945 Direct inquiries regarding fiscal matters to: G. Carol Fitzpatrick Grants Management Office National Institute of Arthritis and Musculoskeletal and Skin Diseases Westwood Building, Room 722A Bethesda, MD 20892 Telephone: (301) 594-9974 FAX: (301) 594-9950 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance Nos. 93.846, 93.847, and 93.866. Awards will be made under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 410, 78th Congress, as amended, 42 USC 241 and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. The Public Health Service (PHS) strongly encourages all grant recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. This is consistent with the PHS mission to protect and advance the physical and mental health of the american people. From owner-sci-resources@net.bio.net Tue Apr 05 23:00:00 1994 Path: biosci!biosci!not-for-mail From: Dave Kristofferson Newsgroups: bionet.sci-resources Subject: NIH GUIDE - RFA CA-94-012 - V23(13) 04/01/94 Date: 5 Apr 1994 17:02:12 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 335 Approved: biosci-moderator@net.bio.net Distribution: bionet Message-ID: <2nsu64$43f@net.bio.net> NNTP-Posting-Host: net.bio.net $$XID RFA CA94012 CA-94-012 P1O1 *************************************** HOSPICE AND PALLIATIVE CARE EDUCATION PROGRAMS NIH GUIDE, Volume 23, Number 13, April 1, 1994 RFA: CA-94-012 P.T. National Cancer Institute Letter of Intent Receipt Date: May 2, 1994 Application Receipt Date: June 16, 1994 PURPOSE The National Cancer Institute (NCI) invites grant applications to create new educational programs to address health professional training in palliative patient care. The intent of this Request for Applications (RFA) is to emphasize NCI's concern for this neglected area with the expectation that any funded programs will act as catalysts to encourage further interest and development in the medical community. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This Request for Application (RFA), Hospice and Palliative Care Education Programs, is related to the priority area of Educational and Community-based Programs. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238) ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, hospices, units of State and local governments, and eligible agencies of the Federal government. Foreign organizations are not eligible to apply. Applications from minority individuals and women are encouraged. MECHANISM OF SUPPORT Support for this effort will be through the NCI Cancer Education (R25) Award. This award is a flexible, curriculum-driven program aimed at developing and sustaining innovative and, possibly, unique educational approaches that ultimately will have an impact on reducing cancer incidence, mortality, and morbidity, as well as on improving the quality-of-life of cancer patients and their families. The current guidelines for the Cancer Education Program (R25) may be obtained from the program director listed under INQUIRIES. Applicants will be responsible for the planning, direction, and execution of the proposed project. The total project period for each application submitted in response to this RFA may not exceed three years. The earliest feasible start date for the initial award will be September 1994. It is anticipated that the average amount of direct costs awarded per grant will range from $50,000 to $100,000 depending upon the proposed program. Indirect costs will be allowed at the rate of eight percent of total direct costs (exclusive of equipment). This RFA is a one-time solicitation. Future competitive continuation applications will compete with all other applications in the Cancer Education Grant Program (R25). Should the NCI, however, determine that there is a sufficient program need, a new request for competitive continuation and/or new applications will be announced. FUNDS AVAILABLE For FY 1994, $500,000 in total costs will be available for, it is estimated, some five to seven new awards. This funding level is dependent on the receipt of a sufficient number of applications of high scientific merit. A greater or lesser amount of dollars and number of awards may be negotiated based on the quality of the applications and the availability of funds. RESEARCH OBJECTIVES Background There are few formally structured programs for training in palliative patient care available in the United States. There are far too few health care professionals who have been trained or have an interest in dealing with this phase of a patient's disease. The Hospice movement in this country, through its own efforts, has developed largely outside mainline, established treatment and educational centers. In September 1990, NCI sponsored a workshop on cancer pain. Although the focus of this meeting was on the need for state-of-the-art technology transfer for pain management, the conference did at that time specify an urgent need for additional educational and training programs in palliative care. At the National Cancer Advisory Board meeting on May 6, 1992, a mini-symposium, "Living with Cancer," once again emphasized the necessity for training and education in this area. In response to these concerns, at the end of FY 1992, the NCI funded at a level of almost $1.3 million 15 of 55 applications for its RFA CA-91-25 which was entitled: "Cancer Education Programs in Pain Management, Rehabilitation, and Psychosocial Issues." In addition, in FY 1993, RFA CA-93-35, "Cancer Pain Management in the Outpatient Setting" was announced. Other This RFA proposes to stimulate medical schools, schools of nursing, cancer centers, oncology divisions, and other health professional entities to design methodologies for the education and training of health care professionals in hospice and palliative care. Traditionally, the nursing profession has been more involved with this phase of patient care than physicians. Hospices have had to struggle with physician recruitment. A major challenge is to train more physicians in a team approach to palliation. An important target group for reaching this goal would be medical students during their clinical training years. At a minimum, what a hospice is, issues of hospice care, and the practical aspects of interaction with patients and their families should be considered. Hospices, either individually or in regional settings in collaborative arrangements with other medical centers are particularly encouraged to submit applications in response to this RFA. The development of hospices in academically oriented settings is definitely encouraged. The NCI hopes to stimulate multi-disciplinary, team approaches to palliative care by encouraging a variety of educational programs aimed at medical students, physicians, other health professionals, and hospice personnel. The ultimate goal is to benefit cancer patients and their families. Applicants can design curricula, short courses, interactions with patients and families, and other effective approaches for training one or more of the target groups mentioned above. For example, programs could involve medical students taking a one month elective or doing a one or two month rotation in a hospice or home health care setting. Residents or practicing physicians could have specifically constructed opportunities in their regular or continuing education to become more cognizant of palliative care including cancer pain management and related psychosocial issues in a hospice setting. These multi-disciplinary programs will require the integration of several el